Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Plasmodium falciparum malaria vaccines in development.

Vekemans J, Ballou WR.

Expert Rev Vaccines. 2008 Mar;7(2):223-40. doi: 10.1586/14760584.7.2.223. Review.

PMID:
18324891
2.

Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW.

J Infect Dis. 2008 Feb 15;197(4):519-26. doi: 10.1086/526787.

3.

Long-term asymptomatic carriage of Plasmodium falciparum protects from malaria attacks: a prospective study among Senegalese children.

Males S, Gaye O, Garcia A.

Clin Infect Dis. 2008 Feb 15;46(4):516-22. doi: 10.1086/526529.

PMID:
18199040
4.

Impaired cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin.

Cholera R, Brittain NJ, Gillrie MR, Lopera-Mesa TM, Diakité SA, Arie T, Krause MA, Guindo A, Tubman A, Fujioka H, Diallo DA, Doumbo OK, Ho M, Wellems TE, Fairhurst RM.

Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):991-6. doi: 10.1073/pnas.0711401105. Epub 2008 Jan 11.

5.

Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting.

Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Koné A, Diallo DA, Raza A, Kai O, Marsh K, Plowe CV, Doumbo OK, Moulds JM.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17471-6. Epub 2007 Oct 24.

6.

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.

Bejon P, Ogada E, Mwangi T, Milligan P, Lang T, Fegan G, Gilbert SC, Peshu N, Marsh K, Hill AV.

PLoS One. 2007 Aug 15;2(8):e707.

7.

Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation.

Moorthy V, Reed Z, Smith PG; WHO Study Group on Measures of Malaria Vaccine Efficacy.

Vaccine. 2007 Jul 9;25(28):5115-23. Epub 2007 Feb 2.

PMID:
17577487
8.

Hemoglobin variants and disease manifestations in severe falciparum malaria.

May J, Evans JA, Timmann C, Ehmen C, Busch W, Thye T, Agbenyega T, Horstmann RD.

JAMA. 2007 May 23;297(20):2220-6.

PMID:
17519411
9.

X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria.

Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA.

PLoS Med. 2007 Mar;4(3):e66.

11.

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.

Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR.

Lancet. 2005 Dec 10;366(9502):2012-8.

PMID:
16338450
12.

Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait.

Williams TN, Mwangi TW, Wambua S, Peto TE, Weatherall DJ, Gupta S, Recker M, Penman BS, Uyoga S, Macharia A, Mwacharo JK, Snow RW, Marsh K.

Nat Genet. 2005 Nov;37(11):1253-7. Epub 2005 Oct 16.

13.

Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases.

Williams TN, Mwangi TW, Wambua S, Alexander ND, Kortok M, Snow RW, Marsh K.

J Infect Dis. 2005 Jul 1;192(1):178-86. Epub 2005 May 31.

14.

Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali.

Dicko A, Mantel C, Kouriba B, Sagara I, Thera MA, Doumbia S, Diallo M, Poudiougou B, Diakite M, Doumbo OK.

Trop Med Int Health. 2005 Jun;10(6):550-6.

15.

An immune basis for malaria protection by the sickle cell trait.

Williams TN, Mwangi TW, Roberts DJ, Alexander ND, Weatherall DJ, Wambua S, Kortok M, Snow RW, Marsh K.

PLoS Med. 2005 May;2(5):e128. Epub 2005 May 31.

16.

The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens.

Cabrera G, Cot M, Migot-Nabias F, Kremsner PG, Deloron P, Luty AJ.

J Infect Dis. 2005 May 15;191(10):1631-8. Epub 2005 Apr 12.

PMID:
15838789
17.

Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya.

Williams TN, Wambua S, Uyoga S, Macharia A, Mwacharo JK, Newton CR, Maitland K.

Blood. 2005 Jul 1;106(1):368-71. Epub 2005 Mar 15.

18.

Host polymorphisms and the incidence of malaria in Ugandan children.

Parikh S, Dorsey G, Rosenthal PJ.

Am J Trop Med Hyg. 2004 Dec;71(6):750-3.

PMID:
15642965
19.

Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection.

Meraldi V, Nebié I, Tiono AB, Diallo D, Sanogo E, Theisen M, Druilhe P, Corradin G, Moret R, Sirima BS.

Parasite Immunol. 2004 Jun-Jul;26(6-7):265-72.

20.

Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in highland and nearby lowland malaria-endemic areas of Kenya.

Moormann AM, Embury PE, Opondo J, Sumba OP, Ouma JH, Kazura JW, John CC.

Trans R Soc Trop Med Hyg. 2003 Sep-Oct;97(5):513-4.

PMID:
15307413

Supplemental Content

Support Center